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tor vehicle accidents and hip fractures from falls. Evi-
dence exists showing greater risk of adverse outcomes
with higher doses of these drugs regardless of drug half-
life. Initial administration of lower doses to elderly and
debilitated patients is generally recommended for benzo-
diazepine hypnotics. We analyzed whether these recom-
mendations are generally followed when prescribing
these drugs to inpatients. METHODS: Demographic and
hospital information for all patients receiving fluraze-
pam, triazolam, or temazepam between January 1998
and June 2000 was extracted from Solucient’s Projected
Inpatient International Classification of Clinical Services
(pICCS) database. This database contains demographic,
hospital, clinical, and detailed service level information
for inpatients from over 150 short-term, non-federal, US
hospitals. The percent of elderly patients (over age 65) re-
ceiving the recommended dose was determined. The rela-
tionship of patient age, hospital teaching status, bed size,
and geographic region on the likelihood of following dos-
ing recommendations was analyzed. RESULTS: We ex-
tracted information for 14,929 inpatients receiving flu-
razepam, 8,147 inpatients receiving triazolam, and 125,625
patients receiving temazepam. Among elderly patients re-
ceiving one of these drugs, 72.1% of patients receiving
flurazepam, 49.8% of patients receiving temazepam, and
7.1% of patients receiving triazolam received the recom-
mended dose. For all three drugs, patient age was directly
correlated with the likelihood of receiving the recom-
mended dose. There was no consistent relationship be-
tween teaching status, hospital bed size, or geographic re-
gion and the likelihood of receiving the recommended
dose, although teaching hospitals were much more likely
than non-teaching hospitals to provide the recommended
dose for temazepam and triazolam (OR 5.3 CI 4.9–5.8
for temazepam; OR 2.7 CI 2.2–3.2 for triazolam). CON-
CLUSIONS: Many elderly inpatients are prescribed higher
than recommended doses of hypnotic benzodiazepines,
suggesting need for systemic interventions to avert ad-
verse outcomes.
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OBJECTIVES: The detrimental effects of hospitalisation
and developments in psychopharmaceutical, psychother-
apeutic and social treatments led to deinstitutionaliza-
tion. Proxies of patients, relatives or friends, have had to
learn to cope with caregiving tasks. Facilitating the cop-
ing of the caregivers should ensure a better quality of
caregiving, notably in terms of therapeutical observance.
An exhaustive literature review found 9 instruments for
caregivers of schizophrenic patients. Five of them are self
administered, but none of those covering mental, psycho-
logical and social fields have been widely validated and
accepted within the scientific community, none are avail-
able in French. We report the first step of development of
a specific, multidimensional, self-administered instru-
ment measuring the quality of life of non-institutional
caregivers of schizophrenic patients. METHODS: Face-
to-face interviews were conducted with non-institutional
caregivers of schizophrenic patients. Their content was
analysed to generate a large number of candidate items
covering all-important aspects of caregivers’ quality of
life. Eighteen interviews were performed: 11 mothers and
7 fathers aged from 48 years to 71. RESULTS: Content
analysis identified topics covering mental (worrying,
emotional over-involvement, and suffering, guilt, fair of
stigma, of future, loneliness, disillusion, anxiety, feeling
of usefulness, self esteem . . . ) physical (fatigue, disrup-
tion of sleep . . . ) and social (relationships with the pa-
tient, friends, relatives, health workers, occupation, lei-
sure . . . ) fields. Negative as well as positive impact was
identified. CONCLUSIONS: These results were compared
to the domains described in the literature. This step led to
the generation of about 100 questions and the validity of
this questionnaire will be studied on 400 caregivers.
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OBJECTIVES: To assess differences in the health care re-
source use of patients who received selective serotonin
reuptake inhibitor (SSRI) antidepressants. METHODS:
Retrospective analysis of administrative medical claims
from 1/97–12/99 was conducted using Protocare Sci-
ences’ Managed Care Database. Patients were catego-
rized as early discontinued or continued (6 months vs.

6 months therapy), then as non-switched or switched
(one agent vs. one agent). Total health care costs were
compared across these categories. RESULTS: Under half
(48%) of the 11,119 SSRI users studied continued antide-
pressant therapy for at least 6 months. Two-thirds of all
patients received monotherapy; 19% switched agents
(44% of switches were in the first three months of ther-
apy); 15% used multiple agents. Eight percent of patients
who discontinued early had switched agents within the
specified 6 month period; 90% of these switches occurred
in the first three months. For patients who continued ther-
apy for 
6 months, the average total health care charges
per patient per month (PPPM) during the first three therapy
months were $906 (switch by third month), $568 (switch
by sixth month), $496 (switch by twelfth month) and $375
(switch after twelfth month). PPPM charges in the first six
